Intracellular mechanisms of tumor cells’ immunoresistance

  • Justyna Hermanowicz 1Department of Pharmacodynamics, Medical University of Bialystok, Białystok, Poland; 2Department of Clinical Pharmacy, Medical University of Bialystok, Białystok, Poland https://orcid.org/0000-0002-3985-4244
  • Beata Sieklucka Department of Pharmacodynamics, Medical University of Bialystok, Białystok, Poland https://orcid.org/0000-0001-8384-7116
  • Krzysztof Nosek Department of Pharmacology and Toxicology, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland https://orcid.org/0000-0002-4248-6841
  • Dariusz Pawlak Department of Pharmacodynamics, Medical University of Bialystok, Białystok, Poland https://orcid.org/0000-0002-3751-0608

Abstract

One of the main mechanisms for avoiding immune response by cancer cells is mediated by inducing an immunosuppressive environment in the tumor following activation of immune checkpoints, i.e. PD-1 or CTLA-4 receptor inhibitors on T lymphocytes. Interaction inhibition between PD-1 or CTLA-4 and their ligands (PD-L1, CD80, and CD85) leads to unblocking of the T-lymphocyte function, and thus destroys cancer cells. Certain intracellular signaling pathways are also involved in the development of tumor cell immunoresistance. Immunosuppressive pathways’ activation blocking may increase the immunological anti-tumor control.

Published
2020-04-22
Section
Articles